Samsung BioLogics Co Ltd 207940

Morningstar Rating
₩1.37M −48,000.00 (3.39%)
View Full Chart

Company Report

Price vs Fair Value

207940 is trading at a LOCK|Tnfmv&Q premium.
Price
₩1.41M
Fair Value
LOCK|Q&b?w!
Uncertainty
LOCK|^<lT
1-Star Price
LOCK|@q?r^?
5-Star Price
LOCK|W&vl^%
Economic Moat
LOCK|#l^LV
Capital Allocation
LOCK|NS%Dbvm

Bulls Say, Bears Say

Bulls

Samsung Biologics has the flexibility to increase capacity through acquisitions, allowing it to immediately capture more demand and boost revenue growth.

Bears

A centralized supply chain could backfire if disruptions occur at its main Korean site, jeopardizing its reputation and client contracts.

News

Trading Information

Previous Close Price
₩1.41M
Day Range
₩1.36M–1.40M
52-Week Range
₩1.15M–1.97M
Bid/Ask
₩1.37M / ₩1.37M
Shares Outstanding
48.51M
Market Cap
₩66.26T
Volume/Avg
34,872 / 60,318

Key Statistics

Price/Earnings (Normalized)
42.28
Price/Sales
14.49
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
0.13%

Company Profile

Founded in 2011, Samsung Biologics, or Samsung Bio, is the largest contract development, research, and manufacturing organization, or CDRMO, globally in terms of manufacturing capacity. The company has 785,000 kiloliters of capacity as of 2025, with plans to acquire another 60,000 kL plant in Maryland in 2026. Samsung Bio entered the research business in June 2025, making it a full-service company offering clients preclinical, front-to-end service. It spun off Samsung Bioepis in October 2025 after its acquisition in 2022, which develops biosimilars for its own pipeline. The spinoff was meant to make Samsung Bio a pure play CDMO business. Samsung C&T and Samsung Electronics own about 43% and 31% of Samsung Bio, respectively. The company competes with Wuxi Biologics, Lonza, and Fujifilm.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Core
Total Number of Employees
5,273

Competitors

Valuation

Metric
207940
02269
CRL
Price/Earnings (Normalized)
42.2829.4034.99
Price/Book Value
7.583.604.93
Price/Sales
14.497.334.08
Price/Cash Flow
25.9419.8925.28
Price/Earnings
207940
02269
CRL

Financial Strength

Metric
207940
02269
CRL
Quick Ratio
0.002.640.86
Current Ratio
2.023.321.41
Interest Coverage
75.0967.520.05
Quick Ratio
207940
02269
CRL

Profitability

Metric
207940
02269
CRL
Return on Assets (Normalized)
—10.38%6.92%
Return on Equity (Normalized)
—14.65%16.59%
Return on Invested Capital (Normalized)
—11.25%9.94%
Return on Assets
207940
02269
CRL

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|&X<YC&!LOCK|qYxlD$135B
Regeneron Pharmaceuticals Inc
REGN
LOCK|!Vs&NpDLOCK|jN%Zl$99B
Moderna Inc
MRNA
LOCK|hz^&#RLOCK|!>$84B
argenx SE ADR
ARGX
LOCK|@CJ#>!>LOCK|p^S$59B
BeOne Medicines Ltd ADR
ONC
LOCK|v?$Qk!LOCK|gsv$48B
Royalty Pharma PLC Class A
RPRX
LOCK|M?@!!w&LOCK|$@^sj$31B
Incyte Corp
INCY
LOCK|fTKwX?LOCK|>X$24B
BioNTech SE ADR
BNTX
LOCK|wc?G$sLOCK|zy$21B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|l^@$F>lLOCK|##jw@$21B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|yQ?%WL<LOCK|zLv$15B

Sponsor Center